Yuishin Izumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuishin Izumi has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Akira Ohta
Department of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan
1 shared publication Akira Tamaoka
Department of Neurology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan
1 shared publication- Akira Watanabe
Medical Innovation Center (MIC), Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
1 shared publication Akito Tanaka
Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan
1 shared publication- Akitsu Hotta
Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
1 shared publication Dai Watanabe
Department of Biological Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan
1 shared publication
Latest Publications
- 24 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (391)
The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), a fatal disease causing progressive loss of motor neurons, still has no effective treatment. We developed a phenotypic screen to repurpose existing drugs using ALS motor neuron survival as readout. Motor neurons were generated from induced pluripotent stem cells (iPSCs) derived from an ALS patient with a mutation in superoxide dismutase 1 (SOD1). Results of the screen showed that more than half of the hits targeted the Src/c-Abl signaling pathway. Src/c-Abl inhibitors increased survival of ALS iPSC-derived motor neurons in vitro. Knockdown of Src or c-Abl with small interfering RNAs (siRNAs) also rescued ALS motor neuron degeneration. One of the hits, bosutinib, boosted autophagy, reduced the amount of misfolded mutant SOD1 protein, and attenuated altered expression of mitochondrial genes. Bosutinib also increased survival in vitro of ALS iPSC-derived motor neurons from patients with sporadic ALS or other forms of familial ALS caused by mutations in TAR DNA binding protein (TDP-43) or repeat expansions in C9orf72. Furthermore, bosutinib treatment modestly extended survival of a mouse model of ALS with an SOD1 mutation, suggesting that Src/c-Abl may be a potentially useful target for developing new drugs to treat ALS.
- 24 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (391)
The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), a fatal disease causing progressive loss of motor neurons, still has no effective treatment. We developed a phenotypic screen to repurpose existing drugs using ALS motor neuron survival as readout. Motor neurons were generated from induced pluripotent stem cells (iPSCs) derived from an ALS patient with a mutation in superoxide dismutase 1 (SOD1). Results of the screen showed that more than half of the hits targeted the Src/c-Abl signaling pathway. Src/c-Abl inhibitors increased survival of ALS iPSC-derived motor neurons in vitro. Knockdown of Src or c-Abl with small interfering RNAs (siRNAs) also rescued ALS motor neuron degeneration. One of the hits, bosutinib, boosted autophagy, reduced the amount of misfolded mutant SOD1 protein, and attenuated altered expression of mitochondrial genes. Bosutinib also increased survival in vitro of ALS iPSC-derived motor neurons from patients with sporadic ALS or other forms of familial ALS caused by mutations in TAR DNA binding protein (TDP-43) or repeat expansions in C9orf72. Furthermore, bosutinib treatment modestly extended survival of a mouse model of ALS with an SOD1 mutation, suggesting that Src/c-Abl may be a potentially useful target for developing new drugs to treat ALS.